SEC 13F Intelligence

Managers / Q4 2018 · view latest →

Cheyne Capital Management (UK) LLP

CIK 0001390457 · STORNOWAY HOUSE, 13 CLEVELAND ROW, LONDON, X0, SW1A 1DH · 011-44(0)2070317450

Reported Value
$106M
Q4 2018
Positions
35
Filings on Record
22
2019–present window
Filed
Feb 5, 2019
original filing

Summary

Cheyne Capital Management (UK) LLP reported $106M in U.S.-listed holdings across 35 positions for Q4 2018.

Its largest position, Nxp Semiconductors N V, represents 10.4% of the portfolio.

Portfolio Metrics

Top-10 Concentration
+54.4%
share of reported value
Largest Position
+10.4%
Nxp Semiconductors N V

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $106MQ4 ’18Q1 ’19: $107MQ2 ’19: $138MQ3 ’19: $158MQ3 ’19Q4 ’19: $165MQ1 ’20: $97MQ2 ’20: $148MQ2 ’20Q3 ’20: $203MQ4 ’20: $198MQ1 ’21: $158MQ1 ’21Q2 ’21: $220MQ3 ’21: $168MQ4 ’21: $154MQ4 ’21Q1 ’22: $159MQ2 ’22: $118MQ3 ’22: $47MQ3 ’22Q4 ’22: $57MQ1 ’23: $32MQ2 ’23: $27MQ2 ’23Q3 ’23: $35MQ4 ’23: $28Mfilingsflow.com

Portfolio Composition

By security type
US DOMESTIC: 61.7%Common Stock: 15.2%YANKEE: 10.9%PRIV PLACEMENT: 5.1%GLOBAL: 2.7%Other: 4.3%
  • US DOMESTIC · 61.7% · $65M
  • Common Stock · 15.2% · $16M
  • YANKEE · 10.9% · $12M
  • PRIV PLACEMENT · 5.1% · $5M
  • GLOBAL · 2.7% · $3M
  • Other · 4.3% · $5M

Quarter-over-Quarter Changes full breakdown →

IssuerMoveShare ΔShares nowValue ΔValue now
NXP SEMICONDUCTORS N VNEW+11.00M11.00M+$11M$11M
GUIDEWIRE SOFTWARE INCNEW+7.00M7.00M+$7M$7M
VECTOR GROUP LTDNEW+6.00M6.00M+$6M$6M
LIBERTY MEDIA CORP DELAWARENEW+5.25M5.25M+$5M$5M
CVNACARVANA CONEW+162.7K162.7K+$5M$5M
SPIRIT RLTY CAP INC NEWNEW+5.10M5.10M+$5M$5M
PRICELINE GRP INCNEW+4.50M4.50M+$5M$5M
DYCOM INDS INCNEW+5.00M5.00M+$5M$5M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2018

35 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1NXP SEMICONDUCTORS N VNOTE 1.000%12/010.42%$11M11.00M
2GUIDEWIRE SOFTWARE INCNOTE 1.250% 3/16.38%$7M7.00M
3VECTOR GROUP LTDFRNT 4/15.71%$6M6.00M
4LIBERTY MEDIA CORP DELAWARENOTE 1.000% 1/35.13%$5M5.25M
5CVNACARVANA COhistory →CL A5.03%$5M162.7K
6SPIRIT RLTY CAP INC NEWNOTE 3.750% 5/14.74%$5M5.10M
7PRICELINE GRP INCNOTE 0.900% 9/14.71%$5M4.50M
8DYCOM INDS INCNOTE 0.750% 9/14.39%$5M5.00M
9ELECTRONICS FOR IMAGING INCNOTE 0.750% 9/04.15%$4M4.50M
10ARES CAP CORPNOTE 3.750% 2/03.79%$4M4.00M
11ALLSCRIPTS HEALTHCARE SOLUTNNOTE 1.250% 7/03.66%$4M4.00M
12RDNTRADNET INChistory →COM3.58%$4M372.9K
13WORKDAY INCNOTE 0.250%10/03.51%$4M3.00M
14ILLUMINA INCNOTE 6/13.45%$4M3.00M
15MEDICINES CONOTE 2.500% 1/13.26%$3M4.00M
16BIOMARIN PHARMACEUTICAL INCNOTE 0.599% 8/02.82%$3M3.00M
17CARDTRONICS INCNOTE 1.000%12/02.81%$3M3.20M
18PROSPECT CAPITAL CORPORATIONNOTE 4.950% 7/12.76%$3M3.00M
19TRANSOCEAN INCDEB 0.500% 1/32.69%$3M3.00M
20ABXBARRICK GOLD CORPhistory →COM2.51%$3M196.0K
21APOLLO GLOBAL MGMT LLCCL A SHS2.49%$3M107.4K
22NUANCE COMMUNICATIONS INCDEBT 1.500%11/02.46%$3M3.00M
23MARRIOTT VACATIONS WRLDWDE CNOTE 1.500% 9/12.45%$3M3.00M
24IOVAIOVANCE BIOTHERAPEUTICS INChistory →COM1.56%$2M186.5K
25POLARITYTE INCCOM1.03%$1M80.7K
26INSMED INCNOTE 1.750% 1/10.67%$708,0001.00M
27GGALGRUPO FINANCIERO GALICIA S ASP ADR 10 SH B0.65%$689,00025.0K
28LOMALOMA NEGRA CORPSPONSORED ADS0.63%$668,00060.0K
29BMABANCO MACRO SASPON ADR B0.52%$553,00012.5K
30VIPSHOP HLDGS LTDNOTE 1.500% 3/10.51%$541,000550.0K
31FCXFREEPORT-MCMORAN INCCL B0.47%$497,00048.2K
32SLBSCHLUMBERGER LTDCOM0.47%$494,00013.7K
33BCRXBIOCRYST PHARMACEUTICALSCOM0.38%$404,00050.0K
34ORGENESIS INCCOM NEW0.17%$183,00039.0K
35II VI INCNOTE 0.250% 9/00.05%$50,0003.00M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2023$28M15Feb 12, 202413F-HRchanges · EDGAR ↗
Q3 2023$35M24Oct 27, 202313F-HRchanges · EDGAR ↗
Q2 2023$27M19Jul 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$32M22May 3, 202313F-HRchanges · EDGAR ↗
Q4 2022$57M59Feb 10, 202313F-HRchanges · EDGAR ↗
Q3 2022$47M35Nov 10, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$118M108Aug 5, 202213F-HRchanges · EDGAR ↗
Q1 2022$159M142May 10, 202213F-HRchanges · EDGAR ↗
Q4 2021$154M125Jan 26, 202213F-HRchanges · EDGAR ↗
Q3 2021$168M112Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$220M114Aug 12, 202113F-HRchanges · EDGAR ↗
Q1 2021$158M100May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$198M88Feb 10, 202113F-HRchanges · EDGAR ↗
Q3 2020$203M57Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$148M46Aug 12, 202013F-HRchanges · EDGAR ↗
Q1 2020$97M40May 7, 202013F-HRchanges · EDGAR ↗
Q4 2019$165M43Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$158M40Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$138M42Aug 8, 201913F-HRchanges · EDGAR ↗
Q1 2019$107M35May 10, 201913F-HRchanges · EDGAR ↗
Q4 2018$106M35Feb 5, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.